shutterstock_gonnorrhea

Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

pharmafile | December 16, 2019 | News story | Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma 

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) after it was discovered to have failed to meet its primary endpoint at Phase 2.

Specifically, the candidate, when combined with Bristol-Myers Squibb’s Opdivo and chemotherapy, failed to achieve a clinically significant overall response rate in NSCLC patients with low-to-no expression of PD-L1 in their tumours.

The trial was conducted in partnership with BMS and examined the candidate’s efficacy in 40 UK and US patients.

“We are obviously very disappointed with the outcome of this Phase 2 trial which showed that the triple combination regimen of TG4010, chemotherapy and nivolumab did not sufficiently increase the response rate in this patient population with advanced NSCLC whose tumours express low or undetectable levels of PD-L1,” explained Dr Philippe Archinard, Chairman and CEO of Transgene. “Additional data analyses are still ongoing and the complete study results will be presented at an upcoming scientific conference.

Matt Fellows

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …

Latest content